<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70569">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02002741</url>
  </required_header>
  <id_info>
    <org_study_id>IBUACA CTIL</org_study_id>
    <nct_id>NCT02002741</nct_id>
  </id_info>
  <brief_title>Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants</brief_title>
  <official_title>Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants: A Pilot, Double Blind, Randomized, Placebo-control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if adding paracetamol to ibuprofen is superior to
      ibuprofen only for treatment of patent ductus arteriosus (PDA) in preterm infants.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The incidence of patent ductus arteriosus closure</measure>
    <time_frame>3-10 days after first dose of Ibuprofen + study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>By echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The need for surgical ligation for PDA</measure>
    <time_frame>3-21 days after first dose of Ibuprofen + study drug</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>until discharge home (usually within 2-3 months since recruitment)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Renal and liver function, gastrointestinal complications will be assessed from the patient's medical records</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants</condition>
  <arm_group>
    <arm_group_label>Ibuprofen + Paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 10mg/kg once --&gt; 5mg/kg twice, q 24h for total of 3 doses
+ Intravenous Paracetamol : Loading dose 20mg/kg --&gt; 10 mg/kg q6h for total of 12 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ibuprofen 10mg/kg once --&gt; 5mg/kg twice, q 24h for total of 3 doses
+ Placebo (NaCl 0.9%) , Intravenous , at equal volume to the paracetamol in the paracetamol arm, total of 12 doses given q 6h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h</description>
    <arm_group_label>Ibuprofen + Paracetamol</arm_group_label>
    <other_name>Acetaminophen</other_name>
    <other_name>Acamol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h</description>
    <arm_group_label>Ibuprofen + Placebo</arm_group_label>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm infants born at 24-37 gestational age

          -  diagnosis of Hemodynamically significant patent ductus arteriosus

          -  Medical staff decided to treat with Ibuprofen

          -  Parents have signed informed consent

        Exclusion Criteria:

          -  Contraindication for ibuprofen

          -  Alanine transaminase /Aspartate transaminaseâ‰¥ 200 U/L

          -  Significant congenital heart disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ori Hochwald, MD</last_name>
    <phone>972-4-8542219</phone>
    <email>o_hochwald@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ori Hochwald, MD</last_name>
      <phone>972-4-8542219</phone>
      <email>o_hochwald@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 1, 2013</lastchanged_date>
  <firstreceived_date>November 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>patent ductus arteriosus</keyword>
  <keyword>PDA</keyword>
  <keyword>Preterm</keyword>
  <keyword>Infant</keyword>
  <keyword>Electrocardiography</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Acamol</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>Placebo</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
